Skip to main content
SpringerLink
Log in

New Formulations of Existing Antidepressants

Advantages in the Management of Depression

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

For nearly 50 years, antidepressant drugs have been the first-line treatment for various forms of depression. Despite their widespread use, these medications have significant shortcomings, in particular problems of patient compliance due to adverse effects. The introduction of new formulations of existing antidepressant medications may provide patients with benefits in terms of convenience of use. As a consequence, improvements in compliance may lead to better antidepressant efficiency.

An orally disintegrating formulation of mirtazapine (mirtazapine SolTab®), a once-weekly formulation of fluoxetine, an enantiomer-specific formulation of citalopram (escitalopram), an extended-release formulation of venlafaxine (venlafaxine XR), a controlled-release formulation of paroxetine (paroxetine CR) and intravenous formulations of some of the newer antidepressants have all been evaluated in limited clinical trials. In this article, a review of the pharmacokinetics and clinical evaluations of these formulations is presented.

While there do not appear to be major clinical advantages for the new formulations in terms of antidepressant efficacy, none of them is less efficacious than their older counterpart. Indeed, some of the new formulations are more acceptable to patients (fluoxetine once-weekly, paroxetine CR), others have pharmacokinetic advantages (venlafaxine XR, paroxetine CR), while others may have a faster onset of effect (mirtazapine SolTab®, intravenous formulations). Further evaluation of some formulations is still required (mirtazapine SolTab®, fluoxetine once-weekly), while others (venlafaxine XR, escitalopram) are finding widespread acceptance in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. Norman TR, Leonard BE. Fast acting antidepressants: can the need be met? CNS Drugs 1994; 2: 120–31

    Article  Google Scholar 

  2. Nierenberg AA. Do some antidepressants work faster than others? J Clin Psychiatry 2001; 62Suppl. 15: 22–5

    PubMed  CAS  Google Scholar 

  3. Shelton RS. Cellular mechanisms in the vulnerability to depression and response to antidepressant drugs. Psychiatr Clin North Am 2000; 23: 713–29

    Article  PubMed  CAS  Google Scholar 

  4. Vaidya V, Duman RS. Depression: emerging insights from neurobiology. Br Med Bull 2001; 57: 61–79

    Article  PubMed  CAS  Google Scholar 

  5. Parker G. Classifying depression: should paradigms lost be regained? Am J Psychiatry 2000; 157: 1195–203

    Article  PubMed  CAS  Google Scholar 

  6. Olver JS, Burrows GD, Norman TR. Third generation antidepressants: do they offer advantages over the SSRIs? CNS Drugs 2001; 15: 941–54

    Article  PubMed  CAS  Google Scholar 

  7. Frey R, Schreinzer D, Stimpfl T, et al. Suicide by antidepressant intoxication identified at autopsy in Vienna from 1991–1997: the favourable consequences of the increasing use of SSRIs European Neuropsychopharmacology 2000; 10: 133–42

    CAS  Google Scholar 

  8. Baumann P, Zullino DF, Eap CB. Enantiomers’ potential in psychopharmacology: a critical analysis with special emphasis on the antidepressant escitalopram. Eur Neuropharmacol 2002; 12: 433–44

    Article  CAS  Google Scholar 

  9. de Boer T, Ruigt GSF, Berendsen HHG. The α2-selective adrenoceptor antagonist Org 3770 enhances noradrenergic and serotonergic transmission. Hum Psychopharmacol 1995; 10Suppl. 2: 107–18

    Article  Google Scholar 

  10. de Boer T, Ruigt GSF. The selective α2-adrenoceptor antagonist mirtazapine (Org 3770) enhances noradrenergic and 5HT1 A: mediated serotonergic neurotransmission. CNS Drugs 1995; 4Suppl. 1: 29–38

    Article  Google Scholar 

  11. Pinder RM. The pharmacologic rationale for the clinical use of antidepressants. J Clin Psychiatry 1997; 58: 501–8

    Article  PubMed  CAS  Google Scholar 

  12. Davis R, Wilde MI. Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs 1996; 5: 389–402

    Article  CAS  Google Scholar 

  13. Burrows GD, Kremer CME. Mirtazapine: clinical advantages in the treatment of depression. J Clin Psychopharmacol 1997; 17Suppl. 1: 34S–9S

    Article  PubMed  CAS  Google Scholar 

  14. Kasper S. Clinical efficacy of mirtazapine: a review of metaanalyses of pooled data. Int Clin Psychopharmacol 1995; 10Suppl. 4: 25–35

    Article  PubMed  Google Scholar 

  15. Timmer CJ, Sitsen JMA, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 2000; 38: 461–74

    Article  PubMed  CAS  Google Scholar 

  16. Voortman G, Paanakker JE. Bioavailability of mirtazapine from Remeron tablets after single and multiple oral dosing. Hum Psychopharmacol 1995; 10 Suppl.: S83–96

    Article  CAS  Google Scholar 

  17. Delbressine LPC, Moonen MEG, Kaspersen FM, et al. Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin Drug Invest 1998; 15: 45–55

    Article  CAS  Google Scholar 

  18. van den Heuvel MW, Kleijn HJ, Peeters PAM. Bioequivalence trial of orally disintegrating mirtazapine tablets and conventional oral mirtazapine tablets in healthy volunteers. Clin Drug Invest 2001; 21: 437–42

    Article  Google Scholar 

  19. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. Washington, DC: American Psychiatric Association, 1994

    Google Scholar 

  20. Kennedy S, Vester-Blokland ED, RAPID Study Group. Mirtazapine (Remeron, Sol-Tab) versus sertraline: a prospective onset of action trial. Poster presentation at the 40th Annual meeting of the American College of Neuropsychopharmacology; 2001 Dec 10-14; Kona (HI)

  21. Roose SP, Holland PJ, Hassman HA, Rosenthal M, Rodrigues HE. Multi-site, open label, observational study of the effectiveness and safety of Remeron SolTab (mirtazapine orally disintegrating tablets) in depressed patients who are at least 50 years of age. Presented at the 53rd Institute on Psychiatric Services; 2001 Oct 10–14; Orlando (FL)

  22. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, revised. Am J Psychiatry 2000; 157Suppl. 4: 1–45

    Google Scholar 

  23. Tollefson GD, Holman SL, Sayler ME, et al. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry 1994; 55: 50–9

    PubMed  CAS  Google Scholar 

  24. Barbui C, Hotopf M, Garattini S. Fluoxetine dose and outcome in antidepressant drug trials. Eur J Clin Pharmacology 2002; 58: 379–86

    Article  CAS  Google Scholar 

  25. Roose SP, Glassman AH, Attia E, et al. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 1998; 155: 660–5

    PubMed  CAS  Google Scholar 

  26. Goodnick P. Pharmacokinetic optimisation of therapy with newer antidepressants. Clin Pharmacokinet 1994; 27: 307–30

    Article  PubMed  CAS  Google Scholar 

  27. Judge R. Patient perspectives on once-weekly fluoxetine. J Clin Psychiatry 2001; 62Suppl. 22: 53–7

    PubMed  CAS  Google Scholar 

  28. Wagstaff AJ, Goa KL. Once weekly fluoxetine. Drugs 2001; 61: 2221–8

    Article  PubMed  CAS  Google Scholar 

  29. Montgomery SA, Baldwin D, Shah A, et al. Plasma-level response relationships with fluoxetine and zimelidine. Clin Neuropharmacol 1990; 13 Suppl. 1: S71–5

    Article  PubMed  Google Scholar 

  30. Burke WJ, McArthur-Miller DA. Exploring treatment alternatives: weekly dosing of fluoxetine for the continuation phase of major depressive disorder. J Clin Psychiatry 2001; 62Suppl. 22: 38–42

    PubMed  CAS  Google Scholar 

  31. Schmidt ME, Fava M, Robinson JM, et al. The efficacy and safety of a new enteric coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. J Clin Psychiatry 2000; 61: 851–7

    Article  PubMed  CAS  Google Scholar 

  32. Schmidt ME, Fava M, Zhang S, et al. Treatment approaches to major depressive disorder relapse. Psychother Psychosom 2002; 71: 190–4

    Article  PubMed  Google Scholar 

  33. Fava M, Schmidt ME, Zhang S, et al. Treatment approaches to major depressive disorder relapse. Psychother Psychosom 2002; 71: 195–9

    Article  PubMed  Google Scholar 

  34. Buongiorno PA, Plewes JM, Wilson MG. Cohort experience in 39 psychiatric outpatients with high doses of an enteric-coated weekly formulation of fluoxetine. Clin Drug Invest 2002; 22: 173–9

    Article  CAS  Google Scholar 

  35. Claxton A, de Klerk E, Parry M, et al. Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder. J Clin Psychiatry 2000; 61: 928–32

    Article  PubMed  CAS  Google Scholar 

  36. de Klerk E. Patient compliance with enteric-coated weekly fluoxetine during continuation treatment of major depressive disorder. J Clin Psychiatry 2001; 62Suppl. 22: 43–7

    PubMed  Google Scholar 

  37. Holliday SM, Benfield P. Venlafaxine: a review of its pharmacology and therapeutic potential in depression. Drugs 1995; 49: 280–94

    Article  PubMed  CAS  Google Scholar 

  38. Wellington K, Perry CM. Venlafaxine extended release: a review of its use in the management of major depression. CNS Drugs 2001; 15: 643–69

    Article  PubMed  CAS  Google Scholar 

  39. Muth EA, Haskins JT, Moyer JA, et al. Antidepressant and biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986; 35: 4493–7

    Article  PubMed  CAS  Google Scholar 

  40. Horst WD, Preskorn SH. The pharmacology and mode of action of venlafaxine. Rev Contemp Pharmacother 1998; 9: 293–302

    CAS  Google Scholar 

  41. Klamerus KJ, Maloney K, Rudolph RL, et al. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol 1992; 32: 716–24

    PubMed  CAS  Google Scholar 

  42. Parker V, Pruitt L, Maloney K, et al. Effect of age and sex on the pharmacokinetics of venlafaxine. J Clin Pharmacol 1990; 30: 832

    Google Scholar 

  43. Muth EA, Moyer JA, Haskins JT, et al. Biochemical, neurophysiological and behavioural effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 1991; 23: 191–9

    Article  CAS  Google Scholar 

  44. Merton WA, Sonne SC, Verga MA. Venlafaxine: a structurally unique and novel antidepressant. Ann Pharmacother 1995; 29: 387–95

    Google Scholar 

  45. Troy SM, Dilea C, Martin PT, et al. Bioavailability of once-daily venlafaxine extended release compared with the immediate release formulation in healthy adult volunteers. Curr Ther Res 1997; 58: 492–503

    Article  CAS  Google Scholar 

  46. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd edition, revised. Washington, DC: American Psychiatric Association, 1987

    Google Scholar 

  47. Cunningham L, for the Venlafaxine XR 208 Study Group. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Ann Clin Psychiatry 1997; 9: 157–64

    PubMed  CAS  Google Scholar 

  48. Thomas DR, Nelson DR, Johnson AM. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology 1987; 93(2): 193–200

    Article  PubMed  CAS  Google Scholar 

  49. Hyttel J. Pharmacological characterisation of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1992; 4Suppl. 6: 15–24

    Google Scholar 

  50. Haddock RE, Johnson AM, Langlry PF, et al. Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites. Acta Psychiat Scand 1989; 80Suppl. 350: 60–75

    Google Scholar 

  51. Bang LM, Keating GM. Paroxetine controlled release. CNS Drugs 2004; 18(6): 355–64

    Article  PubMed  CAS  Google Scholar 

  52. Golden RN, Nemeroff CB, McSorley P, et al. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J Clin Psychiatry 2002; 63: 577–84

    Article  PubMed  CAS  Google Scholar 

  53. GlaxoSmithKline. Paxil CR™ (paroxetine hydrochloride) controlled-release tablets prescribing information [online]. Available from URL: http://www.gsk.com

  54. Rapoport MH, Schneider LS, Dunner DL, et al. Efficacy of controlled-release paroxetine in the treatment of late-life depression. J Clin Psychiatry 2003; 64: 1065–74

    Article  Google Scholar 

  55. Trivedi M, Dillingham K, Pitts CD. Paroxetine CR efficacy and tolerability at low doses in the treatment of major depression. World J Biol Psychiatry 2004; 5 Suppl. 1: 94

    Google Scholar 

  56. Laux G, Konig W, Baumann P. Infusion therapie bei Depressionen Ein Leitfaden fur Klinik und Praxis 4. Aufl., Hippokrates Verlag, Stuttgart 1997

    Google Scholar 

  57. Beaumont G. Oral and intravenous clomipramine (anafranil) in depression. J Int Med Res 1973; 1: 361–4

    Google Scholar 

  58. Faravelli C, Broadhurst AD, Ambonetti A, et al. Double-blind trial with oral versus intravenous clomipramine in primary depression. Biol Psychiatry 1983; 18: 695–706

    PubMed  CAS  Google Scholar 

  59. Guelfi JD, Strub N, Loft H. Efficacy of intravenous citalopram compared with oral citalopram for severe depression: safety and efficacy data from a double-blind, double dummy trial. J Affect Disord 2000; 58: 201–9

    Article  PubMed  CAS  Google Scholar 

  60. Konstantinidis A, Stastny J, Ptak-Butta P, et al. Intravenous mirtazapine in the treatment of depressed inpatients. Eur Neuropsychopharmacol 2002; 12: 57–60

    Article  PubMed  CAS  Google Scholar 

  61. Bouchard JM, Nil R. Benefits of citalopram versus viloxazine, both given as an intravenous-to-oral regimen for severe depression [abstract]. Eur Psychiatry 1998; 13 Suppl. 4: 264S

    Article  Google Scholar 

  62. Baumann P, Nil R, Bertschy G, et al. Intravenous treatment of depressive patients with an SSRI, citalopram: clinical and pharmacokinetic aspects [abstract]. Eur Psychiatry 1997; 12Suppl. 2: 106S

    Article  Google Scholar 

  63. Baumann P, Nil R. Citalopram infusion is a useful alternative to tablets in hospitalised patients with depression [abstract]. Eur Psychiatry 1998; 13Suppl. 4: 264S

    Article  Google Scholar 

  64. Tucker GT. Chiral switches. Lancet 2000; 355: 1085–7

    Article  PubMed  CAS  Google Scholar 

  65. Caldwell J. Stereochemical determinants of the nature and consequences of drug metabolism. J Chromatogr A 1995; 694: 39–48

    Article  PubMed  CAS  Google Scholar 

  66. Hutt AJ, Tan SC. Drug chirality and its significance. Drugs 1996; 52Suppl. 5: 1–12

    Article  PubMed  CAS  Google Scholar 

  67. Hyttel J, Bogeso KP, Perregaard J, et al. The pharmacological effect of citalopram resides in the S(+) enantiomer. J Neural Transm Gen Sect 1992; 88: 157–60

    Article  PubMed  CAS  Google Scholar 

  68. Hogg S, Sanchez C. The antidepressant effects of citalopram are mediated by the S (+) not the R(−) enantiomer [abstract]. Eur Neuropsychopharmacol 1999; 9: S213

    Article  Google Scholar 

  69. Montgomery SA, Loft H, Sanchez C, et al. Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol Toxicol 2001; 88: 282–6

    Article  PubMed  CAS  Google Scholar 

  70. Wade A, Lemming OM, Hedegaard KB. Escitalopram 10mg/ day is effective and well tolerated in placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17: 95–102

    Article  PubMed  CAS  Google Scholar 

  71. Burke WJ, Gergel I, Bose A. Fixed dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63: 331–6

    Article  PubMed  CAS  Google Scholar 

  72. Gorman J, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo controlled trials. CNS Spectrums 2002; 7Suppl. 1: 40–4

    PubMed  Google Scholar 

  73. DeVane CL. Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. J Clin Psychiatry 2003; 64Suppl. 18: 14–9

    PubMed  CAS  Google Scholar 

  74. Kilts CD. Potential new drug delivery systems for antidepressants: an overview. J Clin Psychiatry 2003; 64Suppl. 18: 31–3

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No funding was received for the preparation of this article. Associate Professor Trevor Norman has been a funded speaker for Organon, Wyeth, Eli-Lilly and Lundbeck. Both Dr Olver and Associate Professor Norman are currently recipients of a research grant from Eli-Lilly (Australia).

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Melbourne, Austin & Repatriation Medical Centre, Austin Hospital, Heidelberg, Victoria, 3084, Australia

    Trevor R. Norman & James S. Olver

Authors
  1. Trevor R. Norman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James S. Olver
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Trevor R. Norman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Norman, T.R., Olver, J.S. New Formulations of Existing Antidepressants. CNS Drugs 18, 505–520 (2004). https://doi.org/10.2165/00023210-200418080-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200418080-00003

Keywords

Search

Navigation